Target Price Raised on Metals Firm Following Drill Results

Sourced from: https://www.countingpips.com/2019/06/target-price-raised-on-metals-firm-following-drill-results/


In addition, I certify that no portion of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed within this report.

She or members of her family own securities of these firms mentioned in the post: Not one. Members or her of her household are paid by these companies discussed in this article: Not one.
2) The following businesses discussed in this post are equipping sponsors of Streetwise Reviews: None. Click here for significant disclosures about host fees.
3) Opinions and opinions expressed are those of their specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and isn’t a recommendation to purchase or sell any security.
4) This content does not constitute investment advice. Every reader is encouraged to consult with her or his respective financial pro and any action a reader takes because of information presented here is his or her responsibility. By opening this site, every reader accepts and agrees to Streetwise Reports’ terms of use and full authorized disclaimer. This article is not a solicitation for investment. Streetwise Reports doesn’t leave general or specific investment information and the advice on Streetwise Reports should not be regarded as a recommendation to purchase or sell any security. Streetwise Reports will not endorse or recommend the company, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or members of the families, as well as persons interviewed for interviews and articles on the website, may have a long or short position in securities mentioned. Employees, officers, employees or members of the immediate families are prohibited from making purchases or earnings of these securities in the open market or otherwise from the time of their meeting or the decision to compose an article until three business days after the book of the interview or article. The foregoing prohibition does not apply to articles that in substance simply restate previously published firm releases. As of the date of the interview, officers or employees of Streetwise Reports LLC (such as members of the household) own reports of New Pacific Metals, a company discussed in this article.

The intercepts and their implications are discussed in a ROTH Capital Partners report.
Earlier in the week, the New Pacific announced the outcomes of the initial eight holes, infill holes, from its 2019 drill software at Silver Sand, plus they confirmed “the grade and thickness of the deposit,” Reagor indicated.
( Businesses Disclaimer: NUAG:TSX.V; NUPMF:OTCQX,

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
The highlight was 169 grams per ton (169 g/t) of silver over 144.2 meters (144.2m). The average complete intercept of these pockets was 95.4 m hole with a mean grade of 114.7 g/t silver. “The holes demonstrated improved grades and depth than the averages we saw from the 195 holes this past year,” Reagor commented.

ROTH produces a market in stocks of Silvercorp Metals Inc. and as such, buys and sells from customers on a principal basis.
An Associated Person owns equity or debt securities of New Pacific Metals Corp..

At a June 7 research note, analyst Joe Reagor reported the ROTH Capital Partners increased its target price on New Pacific Metals Corp. (NUAG:TSX.V; NUPMF:OTCQX) to CA$3.50 per share from CA$3 on news of positive, high-grade drill results out of Silver Sand at Bolivia. The stock is currently trading at around CA$2.02 per share.
Upcoming catalysts to New Pacific Metals include the release of additional results, which might be expected during the calendar year, however the most important one, based on Reagor, is release of an initial resource estimate as a result later in 2019. “We hope to find the company’s share price rise significantly over the remainder of the year since it gives a steady flow of results,” the analyst noted, adding that the recent increase in precious metals prices may help buoy the stock in a high degree.
)

Resource: Streetwise Reviews   06/10/2019

By The Gold Report

Price Target Raised on Biopharma Ahead of Leukemia Trial Update

Sourced from: https://www.countingpips.com/2019/05/price-target-raised-on-biopharma-ahead-of-leukemia-trial-update/

Disclosure:

ROTH creates a market in shares of ArQule, Inc. and therefore, sells and buys from customers on a principal basis.

In an April 29 study report, analyst Jotin Marango noted the ROTH Capital Partners increased its price target on ArQule Inc. (ARQL:NASDAQ) to $10 per share in anticipation of a clinical evaluation on its own ARQ531 dose escalation study in chronic lymphocytic leukemia (CLL) patients, to be supplied at the European Hematology Association (EHA) Congress this June.

Over the past twelve months, ROTH has received compensation for investment banking services from ArQule, Inc..

Within the past twelve months, ROTH has handled or co-managed a public offering for ArQule, Inc..

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business associations with all the covered companies.

( Firms Disclaimer: ARQL:NASDAQ,
From The Life Science Report

)

Members or her of her family own securities of the firms. She or members of her household are compensated by the companies discussed in this post: Not one.
Two ) The following companies mentioned in this post are equipping sponsors of Streetwise Reviews: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of their particular experts and not of Streetwise Reviews or its officers. The information supplied above is for informational purposes only and isn’t a recommendation.
4) The content doesn’t constitute investment advice. Each reader is encouraged to consult with her or his individual financial professional and any action as a result of information presented here is their own duty, a reader takes. By opening this page, every writer accepts and agrees to Streetwise Reports’ terms of use and total legal disclaimer. This guide is not a solicitation for investment. Reports will not leave investment advice that is specific or general and the advice on Streetwise Reports should not be regarded as a recommendation. Streetwise Reports does not support or recommend the business, products, services or securities of any company.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or associates of their families, in addition to persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or associates of the immediate families are prohibited from making purchases and/or sales of these securities in the open market or otherwise from the time of their meeting or the decision to compose a post until three business days after the publication of this interview or post. The foregoing prohibition does not apply to articles firm releases that are printed are simply restated by that in material.

Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. In addition, I certify that no portion of my compensation was, is or will be, either directly or indirectly, associated with the specific recommendations or opinions expressed in this report.
ROTH includes a Buy rating on ArQule.
The analysis results ArQule will present in six months will be in the number of CLL patients treated at dosages a BTK inhibitor, of ARQ531, Marango noted. This would consist of cohort 6, whose dose has been raised to 65 mg (65 mg) from 45 milligrams, along with the expanded cohort 7, that received 65 mg. (Info from cohort 8, that is receiving 75 mg, likely will not be ready in time for your EHA meeting.)
Their consequences and the data were addressed in a ROTH Capital Partners report.
“We note that there seem to be potential potential buyers than you can find more reversible ” he included, BTK inhibitors in development.

Disclosures from ROTH Capital Partners, ArQule Inc., Company judgment, April 29, 2019

We are increasingly entangled on ArQule,“ and ” stay high conviction buyers of shares that are ARQL,” Marango wrote. The stock is currently trading at about $6.10 per share.
Marango highlighted a update could elicit a favorable market response , especially if patients experienced tumor shrinkage. The data can move to determining positioning and the dose of a Phase 2 research, ArQule closer. Also, mergers and acquisitions speculation may revive around ARQ531.

Source: Streetwise Reports   05/08/2019

Subscribe to our FREE newsletter : www.streetwisereports.com/get-news

Precious Metals Producer ‘Set to Close Transformational Transaction’

Sourced from: https://www.countingpips.com/2019/03/precious-metals-producer-set-to-close-transformational-transaction/


He noted that Great Panther’s 2019 guidance is in line with expectations. Management forecasts production of 3.7–4 thousand oz (3.7–4 Moz) of Ag eq for an all-in sustaining price (AISC) of $13–$15 per ounce. ROTH’s quotes fall within those ranges, together with production at 3.8 Moz of Ag eq with an AISC of $13.21 per oz.

As for Tucano, fantastic Panther is well positioned financially, having over $50 million in cash, to integrate and enhance it, Sekelsky pointed out. Additionally, the miner could benefit from its new larger size and probably greater bargaining power with local buyers, finally visiting “substantial ” savings because of this. Additionally, greater throughput in the mine should translate into reduced costs on a per ounce basis.
)

Source: Streetwise Reports   03/07/2019
( Businesses Disclaimer: GPR:TSX; GPL:NYSE.American,

From The Gold Report
Disclosure:
Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the topic company or companies and its or their securities. In addition, I certify that no portion of my compensation was, is or will be, either directly or indirectly, associated with the specific recommendations or views expressed within this report.

Members or her of her own securities of these businesses mentioned in the article: Not one. She or members of her household are compensated by the following companies mentioned in this article: Not one.
2) The following firms discussed in this post are equipping sponsors of Streetwise Reviews: None. Click here for important disclosures about host fees.
3) Opinions and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and isn’t a recommendation to purchase or sell any security.
4) This article doesn’t constitute investment advice. Every reader is invited to consult with his or her respective financial professional and any action a reader chooses as a result of information presented here’s his or her own duty. By opening this page, every writer agrees and accepts to Streetwise Reports’ terms of usage and complete lawful disclaimer. This article isn’t a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports shouldn’t be thought of as a recommendation to purchase or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of the families, as well as persons interviewed for articles and interviews on the website, may have a long or short position in securities mentioned. Employees, officers, employees or members of their immediate families are prohibited from making purchases or earnings of these securities in the open market or from the time of their meeting or the decision to compose a post prior to three business days following the publication of this interview or article. The foregoing prohibition doesn’t apply to articles that in substance just restate previously printed company releases.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the subsequent 3 months.

ROTH produces a market in shares of fantastic Panther Silver Limited and therefore, buys and sells from customers on a principal basis.

Higher-than-expected costs, which averaged $15.62 per ounce of silver equal (Ag eq), are to blame for its “mostly higher reduction,” Sekelsky commented.

The advantages to be gained from a recently acquired entity, in addition to a review of the company’s 2018 functionality and 2019 guidance, were discussed at a ROTH Capital Partners report.
Sekelsky emphasized these projections do not include any potential production from Beadell’s Tucano mine, that can be predicted to make 145,000–155,000 oz of gold in 2019.

Disclosures out of ROTH Capital Partners, Terrific Panther Silver, Company ruling, March 3, 2019
Additionally affecting operations, at least Q4/18, has been the current restructuring of their Guanajuato mine complex. But those efforts, the transfer to processing higher-margin substance from San Ignacio, should pay off in lower costs at Guanajuato in 2019. “We support direction ’s choice to have a little step back in production in favour of a lower cost structure,” Sekelsky indicated.
Subscribe to our FREE newsletter : www.streetwisereports.com/get-news